Evaluation of hematological changes in critically ill COVID- 19 patients with venous thromboembolism

Document Type : Original Article

Authors
Akbar Hashemi Tayer
Maryam Kamravan
Mohadeseh Moradiparast
Research Center for Noncommunicable Diseases , Jahrom University of Medical Sciences, Jahrom, Iran
10.22034/pjms.2024.2031137.1142
Abstract
Introduction: The COVID-19 disease significantly impacts the blood coagulation system. Some patients with a severe form of COVID-19 are more susceptible to coagulation disorders, disseminated  intravascular coagulation (DIC), and severe inflammatory responses. This study seeks to improve our understanding of coagulation parameters and examine their changes in COVID-19 patients with venous thromboembolism (VTE).
Materials and Methods: In this case-control study, 56 patients with COVID-19 were admitted to the intensive care unit, consisting of 30 patients without venous thromboembolism (VTE) and 26 patients with VTE. Additionally, 30 healthy individuals who provided written informed consent were included in the sampling. Complete blood count (CBC) was conducted using a sysmax hematology analyzer. Prothrombin time (PT), partial thromboplastin time (PTT), and fibrinogen tests were manually performed with dual repeat for clot formation evaluation. Furthermore, d-dimer, and vWF-Ag indices
were determined using the ELISA-based technique.
Results: In the analysis of CBC parameters, a statistically significant difference was noted between critically ill patients with COVID-19 and healthy individuals (p<0.001). There was also a substantial elevation in coagulation panels, fibrinogen, and D-dimer levels in COVID-19 patients with VTE compared to those without VTE and healthy individuals (p<0.001).
Conclusion: COVID-19 patients, particularly those with VTE, exhibit notable variations in blood and coagulation parameters, as well as increased fibrinogen levels, indicating a potential augmentation in the susceptibility to thrombotic events.
Keywords
Blood Parameters
Coagulation Agents
Complete Blood Count
COVID-19
Thromboembolism
1.Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX,
Chong M, et al. Characteristics and Outcomes of 21
Critically Ill Patients With COVID-19 in Washington
State. JAMA. 2020;323(16):1612-4.
2.Connors JM, Levy JH. COVID-19 and its implications
for thrombosis and anticoagulation. Blood.
2020;135(23):2033-40.
3.Terpos E, Ntanasis-Stathopoulos I, Elalamy I,
Kastritis E, Sergentanis TN, Politou M, et al.
Hematological findings and complications of COVID19. Am J Hematol. 2020;95(7):834-47.
4.Panigada M, Bottino N, Tagliabue P, Grasselli G,
Novembrino C, Chantarangkul V, et al.
Hypercoagulability of COVID-19 patients in intensive
care unit: A report of thromboelastography findings
and other parameters of hemostasis. J Thromb
Haemost. 2020;18(7):1738-42.
5.Tang N, Li D, Wang X, Sun Z. Abnormal coagulation
parameters are associated with poor prognosis in
patients with novel coronavirus pneumonia. J Thromb
Haemost. 2020;18(4):844-7.
6.Xiong M, Liang X, Wei YD. Changes in blood
coagulation in patients with severe coronavirus
disease 2019 (COVID-19): a meta-analysis. Br J
Haematol. 2020;189(6):1050-2.
7.Lee SG, Fralick M, Sholzberg M. Coagulopathy
associated with COVID-19. CMAJ.
2020;192(21):E583.
8.Asakura H, Ogawa H. COVID-19-associated
coagulopathy and disseminated intravascular
coagulation. Int J Hematol. 2021;113(1):45-57.
9.Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer
DA, Kahn ML. GPVI and alpha2beta1 play
independent critical roles during platelet adhesion and
aggregate formation to collagen under flow. Blood.
2005;106(4):1268-77.
10.Jackson SP, Nesbitt WS, Kulkarni S. Signaling
events underlying thrombus formation. J Thromb
Haemost. 2003;1(7):1602-12.
11.Klok FA, Kruip M, van der Meer NJM, Arbous MS,
Gommers D, Kant KM, et al. Incidence of thrombotic
complications in critically ill ICU patients with
COVID-19. Thromb Res. 2020;191:145-7.
12.Porfidia A, Valeriani E, Pola R, Porreca E, Rutjes
AW, Di Nisio M. Venous thromboembolism in
patients with COVID-19: systematic review and metaanalysis .Thromb Res. 2020;196:67-74.
13.Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis
E, Stergiou GS, Syrigos K. Venous thromboembolism
in COVID-19: A systematic review and metaanalysis. Vasc Med. 2021;26(4):415-25.
14.Voukalis C, Lip GY ,Shantsila E. Effects of
antithrombotic drugs on the prothrombotic state in
patients with atrial fibrillation: The west Birmingham
atrial fibrillation project. Thromb Res. 2021;200:149-
55.
15.Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay
A, Seyit M, et al. D-Dimer as a potential biomarker for
disease severity in COVID-19. Am J Emerg Med.
2021;40:55-9.
16.Frazer JS, Tyrynis Everden AJ. Emerging patterns of
hypercoagulability associated with critical COVID19: A review. Trends Anaesth Crit Care. 2020;34:4-
13.
17.Mei ZW, van Wijk XM, Pham HP, Marin MJ. Role
of von Willebrand factor in COVID-19 associated
coagulopathy. J Appl Lab Med. 2021;6(5):1305-15.
18.Rostami M, Mansouritorghabeh H, Parsa-Kondelaji
M. High levels of Von Willebrand factor markers in
COVID-19: a systematic review and meta-analysis.
Clin Exp Med. 2022;22(3):347-57.
19.Ladikou EE, Sivaloganathan H, Milne KM, Arter
WE, Ramasamy R, Saad R ,et al. Von Willebrand
factor (vWF): marker of endothelial damage and
thrombotic risk in COVID-19? Clin Med.
2020;20(5):e178.
20.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et
al. Epidemiological and clinical characteristics of 99
cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study. Lancet.
2020;395(10223):507-13.
21.Pozdnyakova O, Connell NT, Battinelli EM,
Connors JM, Fell G, Kim AS. Clinical Significance of
CBC and WBC Morphology in the Diagnosis and
Clinical Course of COVID-19 Infection. Am J Clin
pathol. 2021;155(3):364-75.
22.Elderdery AY, Elkhalifa AM, Alsrhani A, Zawbaee
KI, Alsurayea SM, Escandarani FK, et al. Complete
blood count alterations of COVID-19 patients in
Riyadh, Kingdom of Saudi Arabia. J Nanomater.
2022;2022:1-6.
23.Usul E, Şan İ, Bekgöz B, Şahin A. Role of
hematological parameters in COVID-19 patients in
the emergency room. Biomark Med.
2020;14(13):1207-15.
24.Fan BE, Chong VCL, Chan SSW, Lim GH, Lim
KGE, Tan GB, et al. Hematologic parameters in
patients with COVID-19 infection. Am J Hematol.
2020;95(6):E131-E4.
25.Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al.
Factors associated with death outcome in patients with
severe coronavirus disease-19 (COVID-19): a casecontrol study. Int J Med Sci. 2020;17(9):1281.
26.Hayıroğlu Mİ, Çınar T, Tekkeşin Aİ. Fibrinogen and
D-dimer variances and anticoagulation
recommendations in Covid-19: current literature
review. Rev Assoc Med Bras. 2020;66:842-8.
27.Kangro K, Wolberg AS, Flick MJ. Fibrinogen, fibrin,
and fibrin degradation products in COVID-19. Curr
Drug Targets. 2022;23(17):1593.